MedPath

AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary Tract Cancer (ASCEND-BTC)

Recruiting
Conditions
Biliary Tract Cancer
Interventions
Other: Blood drawing
Registration Number
NCT05667350
Lead Sponsor
Eastern Hepatobiliary Surgery Hospital
Brief Summary

ASCEND-BTC is a prospective, multi-center, observational study aimed at detecting early biliary tract cancer by combined assays of serum protein and cell-free DNA (cfDNA) methylation. The study will enroll approximately 492 participants diagnosed with biliary tract cancer and benign diseases.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
492
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Benign disease armBlood drawingBaseline blood samples will be collected from participants newly diagnosed with benign biliary tract diseases.
Cancer armBlood drawingBaseline blood samples will be collected from participants newly diagnosed with biliary tract cancer.
Primary Outcome Measures
NameTimeMethod
The sensitivity and specificity of the combined model in detection of biliary tract cancers.24 months
Secondary Outcome Measures
NameTimeMethod
The sensitivity and specificity of the combined model in detection of different stages of biliary tract cancers.24 months
The sensitivity and specificity of the combined model in detection of different subtypes of biliary tract cancers.24 months

Trial Locations

Locations (2)

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

🇨🇳

Guangzhou, Guangdong, China

Eastern Hepatobiliary Surgery Hospital

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath